Gilead Sciences
Gilead Sciences, Inc. is an American biopharmaceutical enterprise that discovers, develops, manufactures, and commercializes innovative human therapeutics for life-threatening diseases. The company structures its drug discovery and commercial operations across key therapeutic focus areas: HIV/AIDS, liver diseases including hepatitis B and C, oncology, and cell therapy. Its commercial drug portfolio includes market-leading therapies such as Biktarvy, Descovy, and Genvoya for HIV management, Veklury for COVID-19, Epclusa for hepatitis, Trodelvy, and CAR-T cell therapy Yescarta. Principal revenue drivers comprise global commercial sales of proprietary, patent-protected prescription biopharmaceuticals, complemented by royalties and strategic research licensing partnerships. Gilead serves broad end markets including wholesale drug distributors, retail pharmacy chains, hospital systems, government health programs, and patients across North America, Europe, and international markets. The enterprise occupies a market-leading position as the world's primary provider of HIV antiretroviral therapies and a pioneer in viral disease treatments. Headquartered in Foster City, California, the company's common stock is listed on the Nasdaq Global Select Market under the ticker symbol GILD and is included in the S&P 500 index.
133 of the funds FundTelligence covers report a position in Gilead Sciences.
- Legal name
- GILEAD SCIENCES INC
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 133
Funds holding Gilead Sciences
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 8.96 % (full portfolio disclosed, October 2026)
- Janus Henderson Horizon Biotechnology Fund — Janus Henderson · 5.13 % (largest positions only, September 2026)
- BNP Health Care Innovators — BNP Paribas · 4.65 % (full portfolio disclosed, June 2026)
- Franklin Biotechnology Discovery Fund — Franklin Templeton · 4.54 % (full portfolio disclosed, September 2026)
- UBS Biotech Equity Fund — UBS · 4.2 % (largest positions only, September 2026)
- Polar Capital Global Healthcare Select Fund — Polar Capital · 4.2 % (largest positions only, October 2026)
- Fidelity Global Healthcare Fund — Fidelity · 4.1 % (largest positions only, October 2026)
- AB International Health Care Portfolio — AllianceBernstein · 4.07 % (largest positions only, September 2026)
Showing the 8 largest of 133 funds holding it.